ASSESSMENT OF THE EFFICIENCY OF THE USE OF BIPHENYLDYMETRYDICARBOXYLATE PREPARATION IN NON-ALCOHOLIC FATTY LIVER DISEASE
Specific drug therapy, which is currently proposed, has no evidence base or approval of the FDA or EMEA so far. Objective. To evaluate the efficacy of herbal medicinal product biphenyldimethyldicarboxylate 7.5 mg in non-alcoholic steatohepatitis Material and methods. The study included 30 patients. The drug was prescribed at the dose of 1 capsule 3 times a day. The course of therapy was 90 days. The treatment efficacy with the drug, biphenyldimethyldicarboxylate 7.5 mg, was evaluated by the dynamics of chemistry values and upon the study results of the quality of life using the SF-36 questionnaire. Conclusion. The use of the drug, biphenyldimethyldicarboxylate 7.5 mg, in the treatment of non-alcoholic steatohepatitis patients is accompanied by a statistically significant decrease in the levels of chemistry values: ALT, AST, ALP, γGGT, improvement of the emotional, psychological and physical state of patients. High tolerability of the drug, absence of undesirable eventsare of great importance for the development of patient’s adherence to administration of the drug and achievement of a consistent treatment.